Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:MLTX 29 September 2025 - 8 January 2026

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

MoonLake Immunotherapeutics shares plunged about 85% pre-market Monday after mixed Phase 3 VELA trial results, dropping from around $62 to under $8 and cutting market cap from $3.9 billion to $0.5 billion. The stock had surged days earlier on takeover rumors and clinical optimism. VELA-1 met its primary endpoint, but VELA-2 narrowly missed. Analyst sentiment turned sharply negative after the data release.
29 September 2025
·

Stock Market Today

  • Yangzijiang Shipbuilding Shares Rise as DBS Lifts Price Target Amid Strong Order Backlog
    March 20, 2026, 6:56 PM EDT. Yangzijiang Shipbuilding Holdings Ltd (SGX: BS6) stock gained momentum after DBS raised its price target to SGD 3.60 from SGD 3.01, maintaining a buy rating. Analyst Pei Hwa Ho highlighted the company's robust fundamentals and solid order backlog, signaling revenue stability in the capital-intensive shipbuilding sector. The firm's focus on container vessels, bulk carriers, and high-margin LNG ships benefits from global fleet modernization and new environmental regulations. This upgrade offers DACH investors direct exposure to Asia's industrial recovery amid shifting global trade and supply chain dynamics. The company's 2025 full-year results demonstrated resilience despite sector cyclicality, strengthening investor confidence in its long-term growth prospects.
Go toTop